News | Structural Heart | March 02, 2016

FDA Clears Sapien for Pulmonary Valve

The FDA approval expands use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve replacement procedures

Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards Sapien XT transcatheter heart valve for pulmonic valve replacement procedures. The approval enables the treatment of adult and pediatric patients who suffer from either a narrowed pulmonary valve or moderate or greater pulmonary regurgitation caused by congenital heart disease.

"U.S. approval of the Sapien XT valve for pulmonic procedures provides an important, minimally invasive treatment option for a small group of patients who typically face the burden of multiple open-heart surgeries, oftentimes beginning at birth or during childhood. As risks increase with each open-heart surgery, a non-surgical option can help them receive treatment, recover and return to normal activities sooner," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.

FDA approval of the Edwards Sapien XT valve for pulmonic procedures was supported by data from the multicenter COMPASSION clinical trial and additional clinical data from Europe. As previously indicated, the commercial opportunity related to this approval is small and is factored into 2016 financial expectations.

For more information: www.edwards.com 

Related Content

Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

Home October 15, 2021
Home
Videos | Structural Heart

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

Home October 14, 2021
Home
Videos | Structural Heart

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

Home September 28, 2021
Home
Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

Home September 20, 2021
Home
News | Structural Heart

September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...

Home September 13, 2021
Home
Videos | Structural Heart

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

Home July 14, 2021
Home
News | Structural Heart

June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare ...

Home June 29, 2021
Home
News | Structural Heart

June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and ...

Home June 07, 2021
Home
Feature | Structural Heart | Dave Fornell, Editor

June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic ...

Home June 02, 2021
Home
Feature | Structural Heart

May 26, 2021 — Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated ...

Home May 26, 2021
Home
Subscribe Now